我们是谁的桥梁? 对接受注射性桥梁治疗的华法林患者的描述
Sara R Vazquez1, Connor Jensen2, Aaron S Wilson2
1University of Utah College of Pharmacy, Department of Pharmacotherapy, 30 South 2000 East, Salt Lake City, UT 84112, USA; University of Utah Health Thrombosis Service, 6056 Fashion Square Drive, Suite 2420, Murray, UT 84107, USA.
Thrombosis research
|March 14, 2025
概括
对华法林患者的注射抗凝剂桥梁治疗是常见的,特别是对于那些患有抗脂综合征或VTE的人的胃肠道手术. 一些患者可能不需要桥梁治疗,这表明需要进一步研究.
科学领域:
- 心脏病学 心脏病学
- 血液学 血液学 血液学
- 药理学 药理学是指药理学的学科.
背景情况:
- 可以注射的抗凝血剂桥梁疗法用于在手术期间管理华法林患者.
- 指导桥梁决策的证据有限,需要对患者群体和结果进行进一步研究.
研究的目的:
- 为了确定接受注射抗凝固剂桥梁治疗的患者类型.
- 确定患者群体,以便在未来研究桥梁治疗结果.
主要方法:
- 进行了一项描述性队列研究.
- 包括接受华法林治疗的患者,在2022年1月1日至12月31日期间接受门诊埃诺沙巴林桥接治疗.
- 抗凝血指示,桥梁原因和程序类型被手动审查.
主要成果:
- 181名患者 (华法林人口的9.4%) 经历了244次桥接事件.
- 大多数发作 (67.6%) 是周围手术,主要是胃肠道手术 (39.4%).
- 常见的适应症包括抗脂综合征 (APS),静脉血栓塞栓症 (VTE) 和机械关.
结论:
- 华法林患者通常在胃肠道手术,APS,VTE或机械关时接受埃诺沙巴林桥接.
- 超过三分之一的桥梁患者被归类为中低血栓风险.
- 这些发现表明,可能需要进一步调查或降低桥梁疗法的升级.
相关概念视频
Anticoagulant Drugs: Low-Molecular-Weight Heparins
586
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
586
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.1K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.1K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
446
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
446
Therapeutic Index
4.0K
The therapeutic index of a drug is a key parameter in pharmacology that quantifies the relative safety of a drug by calculating the ratio between the dose that causes toxicity in half the population (50%) to the dose that proves to be effective for half the population (50%). It provides a spectrum of doses for a particular drug ranging from effective to potentially toxic. To illustrate, consider an anticoagulant agent like warfarin. It possesses a narrow window within its therapeutic index to...
4.0K
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
1.2K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.2K
Protein-Drug Binding: Mechanism and Kinetics
227
Protein-drug binding refers to the interaction between drugs and proteins within the body. This binding process can occur intracellularly, involving drug interactions with enzymes or receptors within cells, or extracellularly, involving plasma proteins in the blood.
Various forces drive these interactions, including hydrogen bonds, hydrophobic interactions, ionic bonds, electrostatic interactions, and van der Waals forces. These bonds enable drugs to bind to specific sites on proteins,...
Various forces drive these interactions, including hydrogen bonds, hydrophobic interactions, ionic bonds, electrostatic interactions, and van der Waals forces. These bonds enable drugs to bind to specific sites on proteins,...
227


